Additional IV fluids reduce rates of C-section, time in labor

Whether the optimal guide to hydration is eight glasses of water a day or not, new evidence suggests proper fluid levels are especially important for women in labor. A study, published in the National Center for Biotechnology Information, found those who receiving intravenous (IV) fluid had lower rates of C-sections and shortened overall labor times.

Researchers from Thomas Jefferson University in Philadelphia compiled information from a variety of studies analyzing hydration rates in laboring women to assess how IV fluids affected rates of C-sections and labor. The study covered seven small clinical trials for a total population of 1,215 women, 593 of whom received IV fluids at 250 milliliters per hour and 622 at 125 milliliters per hour. Researchers then compared the two groups for differences in C-sections and time spent in labor.

Results showed that the women receiving 250 milliliters per hours were 6 percent less likely to need a C-section, reducing the total time in labor by an average of 64 minutes and reducing the pushing phase by three minutes on average.

"We've known that it's important for women to stay well hydrated during pregnancy and labor. This study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of C-section, and decrease length of labor," said Vincenzo Berghella, MD, director of maternal fetal medicine and professor at the Sidney Kimmel Medical College at Thomas Jefferson University. "The results are compelling and strongly argue for a change in practice. We have already begun changing practice at Jefferson to give women more fluids in labor, to allow them to have the best chance of delivering vaginally. Recently, we also showed that letting women eat more liberally in labor, especially in early labor, has benefits including shorter labor and no identifiable risks."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.